Clinical trial · Observational
Temperature, Heart and Respiratory Rate Investigation Along With Variability Evaluation and Serum Biomarkers (THRRIVES)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to find a way of detecting infection earlier in patients receiving bone marrow transplant. This is accomplished by continuous individualized monitoring of heart rate, respiratory rate and temperature variability in this patient population. The investigators are collecting data to determine whether or not subtle differences in heart rate, respiratory rate and temperature will help physicians to detect infection earlier in order to begin faster treatment before a patient's condition deteriorates. Blood tests will also be performed to check for certain biomarkers that may indicate infection
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Zephyr Biopatch Device | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Bone Marrow Transplant Patients
- interventionNames
- Device: Zephyr Biopatch Device
Primary outcomes (1)
- measure
- Initiation or broadening of antibiotic for the purpose of treatment of infection
- timeFrame
- Patients are monitored for a period of up to 10 days or until their white blood cell count goes up, which could take an expected average of 20 days
Secondary outcomes (1)
- measure
- Admission to ICU with organ failure or hospital
- timeFrame
- Patients are monitored for a period of up to 10 days or until their white blood cell count goes up, which could take an expected average of 20 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: An expected prolonged period of neutropenia * Completing bone marrow; * Allogeneic and/or autologous transplants OR * Induction chemotherapy Exclusion Criteria: * Inability to obtain written informed consent from patient or legally authorized representative * Ongoing treatment for active infection (not prophylaxis) * Preexisting severe cardiopulmonary disease (defined as an EF 40%, FEV 40%,or interstitial lung disease with pulmonary fibrosis) * On betablockers or calcium channel blockers * Preexisting arrhythmia * Permanent pacemaker * Inability to speak neither English nor French
References
Publications (0)
Data not yet available